Chromium is one of the few minerals with an EU-authorized claim that touches blood glucose directly — which makes it a genuinely useful ingredient for metabolic-health formulations, and also one of the easier ingredients to over-claim around. The distance between what chromium is authorized to say and what “blood sugar support” marketing often implies is a useful case study in the medicinal-by-presentation line covered elsewhere on this site.
The four authorized chromium claims
Following a 2010 EFSA scientific opinion, four chromium health claims are authorized under Commission Regulation (EU) 432/2012, all requiring the food to be at least a “source of chromium” as defined in the Annex to Regulation (EC) No 1924/2006:12
- Chromium contributes to normal macronutrient metabolism
- Chromium contributes to the maintenance of normal blood glucose concentrations
- Chromium contributes to the maintenance or achievement of a normal body weight
- Chromium contributes to the reduction of tiredness and fatigue
The food constituent evaluated and authorized is specifically trivalent chromium — the form found in chromium picolinate and similar supplement forms — not chromium in other oxidation states.2
Why “maintenance of normal blood glucose concentrations” is a narrower claim than it sounds
This is the claim most likely to get stretched in marketing copy, and the wording matters precisely because of what it does not say:
- It is a claim about maintaining an already-normal level — not about lowering an elevated level, managing insulin resistance, or supporting a diagnosed metabolic condition.
- It says nothing about diabetes, prediabetes, insulin sensitivity, or HbA1c— extending the claim into any of those territories moves from an authorized nutrition/health claim into disease-treatment language, which is where the medicinal-by-presentation doctrine applies regardless of the ingredient's legality.3
- EFSA's underlying evaluation was for the general population maintaining normal levels, not a population with an existing glucose-regulation disorder — a formulation marketed specifically at people managing blood sugar problems is implicitly making a claim about a population and effect the authorization doesn't cover.
The practical distinction: “supports normal blood glucose maintenance already within a healthy range” stays inside the authorized claim. “Helps manage blood sugar,” “supports healthy insulin response,” or any framing implying correction of an elevated or dysregulated state moves outside it — not because chromium's science is necessarily wrong, but because that specific claim was never evaluated or authorized.
Why this connects directly to glucose-metabolism formulation generally
This is exactly the boundary flagged in the broader look at medicinal-by-presentation risk: a product can have a completely legal ingredient — chromium, at a compliant dose — and still cross into unauthorized medicinal-product territory purely through marketing language that implies disease management rather than maintenance of a normal function.3 For any glucose-metabolism-positioned formulation, chromium's authorized claim is a genuinely solid anchor — as long as the surrounding copy (product name, category framing, testimonials) doesn't push the claim past what “maintenance of normal blood glucose concentrations” actually authorizes.